Research programme: oncology therapies - Bristol-Myers Squibb/Nerviano Medical Sciences
Latest Information Update: 16 Jul 2016
At a glance
- Originator Bristol-Myers Squibb; Nerviano Medical Sciences
- Developer Nerviano Medical Sciences
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Italy